Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
Valentin Goede,
Paula Cramer,
Raymonde Busch,
Manuela Bergmann,
Martina Stauch,
Georg Hopfinger,
Stephan Stilgenbauer,
Hartmut Döhner,
Anne Westermann,
Clemens M. Wendtner,
Barbara Eichhorst,
Michael Hallek
Affiliations
Valentin Goede
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany;Department of Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Germany
Paula Cramer
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany
Raymonde Busch
Institute of Medical Statistics and Epidemiology, Technical University of Munich, Germany
Manuela Bergmann
Department of Internal Medicine III, University of Ulm, Germany
Martina Stauch
Private practice, Kronach, Germany
Georg Hopfinger
Medical Department III, Paracelsus Medical University Salzburg, Austria
Stephan Stilgenbauer
Department of Internal Medicine III, University of Ulm, Germany
Hartmut Döhner
Department of Internal Medicine III, University of Ulm, Germany
Anne Westermann
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany
Clemens M. Wendtner
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany;Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Schwabing Hospital, Munich, Germany
Barbara Eichhorst
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany
Michael Hallek
Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany;Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Germany
This study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic Leukemia Study Group on first-line treatment with fludarabine plus cyclophosphamide, fludarabine, or chlorambucil. Patients with two or more comorbidities and patients with less than two comorbidities differed in overall survival (71.7 versus 90.2 months; P
